News

Of the 45 patients enrolled in this study, 16 patients from four European centers have completed two years of Rheos hypertension (HT) therapy. Blood pressure measurements were taken

A total of 35 subjects, of whom 29 received BTT-1023, were enrolled into the placebo-controlled study. BTT-1023 was generally well tolerated and no serious adverse events were reported

Under the terms of the agreement, Merck will provide Nuevolution with an upfront payment, research funding and milestone payments as candidate molecules progress through preclinical and clinical development

The offer price represents a 14.6% premium to Zentiva’s April 30, 2008 closing price of CZK916 the last day before PPF Group made an announcement of its intended

The first-line Indolent trial (FIT), which evaluated the use of Zevalin as first-line consolidation therapy in follicular lymphoma patients, was sponsored by Bayer Schering Pharma, which has exclusive

The debentures are convertible into company common stock at $1.10 per share. After six months, the debentures will amortize through thirty equal installments. The company may at its

Subject to final issuance from the Patent and Trademark Office, the newly allowed claims are expected to expire in 2024, taking into account an anticipated patent term adjustment

In addition to the 10-year market exclusivity, incentives relating to the designation include assistance from the European Medicines Evaluation Agency in developing a protocol to maximize the chance

Other owners, Andrew Adkisson and Emily Wilder, will also remain with the company. Mr Adkisson will be responsible for the company’s central fabrication operations and Ms Wilder assumes